Microneedle-mediated transdermal delivery of siRNA-loaded nanoparticles for atopic dermatitis therapy by disrupting cuproptosis-pyroptosis crosstalk - PubMed
2 hours ago
- #microneedle delivery
- #siRNA nanoparticles
- #atopic dermatitis
- A dual-functional microneedle system, CaP-siSlc31a1@BSP, was developed for atopic dermatitis therapy.
- It delivers siRNA targeting SLC31A1 to disrupt cuproptosis-pyroptosis crosstalk via epigenetic regulation.
- The system effectively alleviates skin inflammation, epidermal hyperplasia, and pruritus in AD-like mouse models.
- SLC31A1 is identified as a driver of copper overload and cuproptosis, promoting GSDMA-dependent pyroptosis.
- This approach offers a synergistic transdermal drug-gene strategy with therapeutic potential for AD.